

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

WON THE SECOND CLASS AWARD OF THE STATE TECHNOLOGICAL INVENTION AWARD IN THE PRC

This announcement is made by LifeTech Scientific Corporation (the “**Company**”) on a voluntary basis to keep the shareholders and potential investors informed of its latest business development in the science and technology industry.

The board of directors of the Company (the “**Board**”) is pleased to announce that on 9 January 2015, the Company has been awarded the Second Class Award of the State Technological Invention Award* (國家技術發明獎二等獎) in 2014 (the “**Award**”) by the State Council of the People’s Republic of China (the “**PRC**”) in recognition of the “New Equipment, New Technology and Clinical Application of Ventricular Septal Defect Intervention Therapy” developed and invented by the Company and a team of clinical experts.

The Award is one of the State Science and Technology Prizes (the “**SSTP**”) for technological invention in the PRC. The SSTP is the highest honor in the PRC science and technology field for acknowledging individuals and organizations that have made remarkable contributions to scientific and technological progress, thereby promoting the development of science and technology.

This Award is given to acknowledge the Company’s outstanding achievement in inventing the symmetrical double disk occluder system and biological ceramic coating occluder for the minimally invasive treatment of a serious heart disease, Congenital Ventricular Septal Defect, (“**VSD**”), creating the corresponding clinical operation rules, realizing the wide clinical application of VSD minimally invasive treatment technology and offering a minimally invasive treatment method which is

efficient and effective. Winning of the Award serves as a valuable testament to the Company's leading position in the field of minimally invasive treatment of VSD in the PRC.

The Company and its subsidiaries (the "**Group**") are dedicated to researching, developing, manufacturing and marketing advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Board believes that the Award will bring positive influences on the Group's business and it will be a strong motivation to the Group to further engage in the research, development and invention of medical devices and technology, which helps to accomplish the Company's long-term goal in becoming the market leader in the medical device and technology industry.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Chairman and Executive Director

Hong Kong, 21 January 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. ZHAO Yiwei Michael being executive directors of the Company; Mr. WU Jianhui, Mr. MARTHA Geoffrey Straub, Dr. LIDDICOAT John Randall and Mr. JIANG Feng being non-executive directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Luming and Mr. ZHOU Gengshen being independent non-executive directors of the Company.

** For identification purpose only.*